Here are five points:
1. The company, which develops regenerative therapies for degenerative spine diseases, earned $14 million in funding.
2. DiscGenics now has $21.7 million in total funding.
3. DiscGenics board of directors’ long-term investors and Mitsubishi UFJ Capital Co. led the round.
4. The company is developing IDCT, an injectable cell therapy for degenerative disc disease.
5. The funding will support the company’s clinical development of IDCT in the U.S and Japan as well as boost its cell therapy manufacturing process for Phase III clinical and commercial production.
More articles on biologics:
Do biologic knee joint grafts improve with bone marrow concentrate? 5 things to know
Spine biologics market to make it big in the near future
US Stem Cell Clinic under fire after FDA investigation found ‘significant deviations’ — 5 key points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
